Author's reply re: Changes in anti‐müllerian hormone levels as a biomarker for ovarian reserve after ultrasound‐guided high‐intensity focused ultrasound treatment of adenomyosis and uterine fibroid

Kim TE, Tae-Eung Kim, Т. В. Ким
BJOG: An International Journal of Obstetrics & Gynaecology · 2017 · vol. 125(4) , pp. 508–509 · doi:10.1111/1471-0528.14979 · PMID:29148166 · W4246658397
letter OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper discusses changes in anti-Müllerian hormone (AMH) levels as a biomarker for ovarian reserve following ultrasound-guided high-intensity focused ultrasound (HIFU) treatment of adenomyosis and uterine fibroids.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Leiomyoma Anti-Mullerian Hormone Biomarkers Female Humans Ovarian Reserve Uterine Neoplasms

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (4)

Source provenance

europepmc
last seen: 2026-08-12T06:07:16.479679+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:07.505861+00:00
License: CC0 · commercial use OK